What is the recommended management for a neovascular membrane at [LOCATION]?

Management of Neovascular Membrane

Intravitreal anti-VEGF therapy is the first-line treatment for neovascular membranes, with ranibizumab, aflibercept, bevacizumab, and brolucizumab all demonstrating efficacy in achieving membrane regression and visual improvement.

Treatment Algorithm

Initial Management

Start with intravitreal anti-VEGF injections as primary therapy 1. The choice of agent depends on availability and specific clinical context:

• Brolucizumab: Achieved superior reductions in central subfield thickness compared with aflibercept, with fewer patients having subretinal, intraretinal, and sub-RPE fluid 1
• Aflibercept and Ranibizumab: No statistically significant differences in safety or efficacy at 1 year 1
• Bevacizumab: Effective but caution advised with PRN dosing as it may be slightly less effective than other anti-VEGF regimens 1

Dosing Regimens

Three evidence-based approaches exist 1:

1. Fixed monthly dosing (every 4 weeks): Maintains initial visual gains long-term
2. PRN (as-needed): Comparable efficacy to monthly over 1 year but may not maintain gains with longer follow-up
3. Treat-and-extend: Frequently used in clinical practice with similar efficacy to monthly dosing

The treat-and-extend regimen offers a practical balance between efficacy and treatment burden 1.

Location-Specific Considerations

Peripapillary Location

For peripapillary neovascular membranes:

• Anti-VEGF therapy remains effective 2, 3
• Laser ablation with broad treatment margins reduces recurrence (19.2% recurrence rate) 4
• Monitor for bilateral involvement (19.8% develop second-eye involvement) 4
• If associated with inflammatory conditions (sarcoidosis, IIH), combine anti-VEGF with systemic immunomodulatory therapy 2, 3

Inflammatory Etiology

When neovascularization is inflammatory in origin 5:

• Combine anti-VEGF injections with anti-inflammatory/immunosuppressive therapy
• Median 7 injections typically needed
• 80% achieve improved visual outcomes with combined approach
• Intensive follow-up is fundamental for managing both inflammation and neovascularization

Associated with Choroidal Nevi

For nevus-associated membranes 6:

• Start with intravitreal bevacizumab (73% achieve complete or partial regression)
• If unresponsive after initial treatment, add photodynamic therapy (PDT) to bevacizumab
• Some non-vision-threatening cases may be observed

Treatment Response Monitoring

Expect the following outcomes:

• Visual acuity: 50% maintain 20/40 or better at 5 years 1
• Anatomical improvement: Significant reduction in subfoveal retinal thickness
• Membrane regression: Complete or partial regression in majority of cases

Critical Pitfalls to Avoid

1. Do not use PRN bevacizumab as first choice if other agents available—it shows slightly inferior outcomes 1
2. Do not discontinue anti-VEGF therapy for RPE tears—these may occur with or without treatment and are not a contraindication to continued therapy 1
3. Do not treat inflammatory neovascularization with anti-VEGF alone—always address underlying inflammation simultaneously 5, 3
4. Do not assume unilateral disease will remain unilateral—nearly 20% develop fellow eye involvement 4

Safety Considerations

All anti-VEGF agents carry similar risks 1:

• Endophthalmitis (≤1.0% cumulative at 1 year)
• Retinal tear or detachment
• Noninfectious inflammation
• Theoretical systemic arterial thromboembolic events (clinical trials remain inconclusive)
• Increased intraocular pressure

No statistically significant differences exist in rates of death, arteriothrombotic events, or venous thrombotic events between ranibizumab, aflibercept, and bevacizumab 1.

Special Populations

Avoid anti-VEGF therapy in pregnant or lactating women—risks have not been studied 1.